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Abstract
Purpose: The aim was to investigate the potential impact of positron emission tomography
(PET)/computed tomography (CT) as compared to PET and CT on the staging of patients with
indolent lymphoma.
Procedures: PET/CTs from 45 patients with indolent lymphoma undergoing staging or restaging
were studied. Clinical follow-up, additional imaging, and histology served as the gold standard.
Results: PET/CT correctly diagnosed 92 nodal regions as positive for lymphomatous involvement
and 458 as disease free vs 68 and 449 for PET and 64 and 459 for CT, respectively. The
respective sensitivities, specificities, and accuracies were 99%, 100%, and 99.8% for PET/CT,
68%, 97.5%, and 92.2% for PET, and 70%, 100%, and 94.7% for CT. PET/CT performed
significantly better than PET (pG0.001 for sensitivity, specificity, and accuracy) and CT (pG0.001
for sensitivity and accuracy). PET/CT also correctly identified significantly more extra-nodal lesions
(22) than CT (14) and PET (nine).
Conclusions: PET/CT provides significantly more accurate information compared to PET and CT
for the staging and re-staging of patients with indolent lymphoma.
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Introduction
M
etabolic imaging with fluorine-18-fluorodeoxyglucose
(FDG) positron emission tomography (PET) has
become the clinical standard for staging and evaluation of
treatment response in patients with non-Hodgkin lymphoma
(NHL) [1–5]. More recently, PET/computed tomography
(CT) has been shown to stage lymphoma with a higher
accuracy than PET alone [6–9]. These studies have focused
on Hodgkin’s disease or aggressive NHL.
Staging of disease has important treatment implica-
tions for indolent NHL (indolent lymphoma). For
example, up to one third of patients with follicular
lymphoma can present with stage I and II disease, and
70% to 90% of mucosa-associated lymphoid tissue
(MALT) lymphomas may present with localized (stage
IE–IIE) disease [10]. In these cases, patients can be
treated with radiation only [11], whereas higher stages
usually require systemic therapy.
However, very few studies have evaluated the role of
FDG PET in patients with indolent lymphoma. Most of these
studies concluded that PET appears useful for the staging of
the follicular subtype but only has a limited usefulness in the
other subtypes of indolent lymphoma [12–15]. Except for a
small study in patients with MALT lymphoma by Perry et
al. [16], no study has evaluated the role of PET/CT in the
staging of indolent lymphoma.
Correspondence to: Martin S. Allen-Auerbach; e-mail: mauerbach@
mednet.ucla.eduFDG uptake in indolent lymphoma appears to be lower
than in aggressive lymphomas [17]. Data on the correlation
between proliferative activity and glycolysis in malignant
tissue, as measured by FDG uptake, are controversial [18,
19]. To date, the correlation between FDG uptake and
proliferative activity specifically in indolent lymphoma has
not been studied in detail.
To our knowledge, to date, no study has investigated the
value of PET/CT over PET and CT for staging of indolent
lymphoma. The aim of the present study was to investigate
the potential impact of PET/CT as compared to PET and CT
on the staging of patients with indolent lymphoma. For a
better understanding of FDG uptake in indolent lymphoma,
we also investigated the correlation between FDG uptake
and proliferative activity as measured by Ki-67 staining.
Patients and Methods
Patients
From March 2004 to September 2006, 301 patients with indolent
lymphoma were referred to our institution for PET/CT imaging. In 45
of these patients (26 male, 19 female, mean age of 56±13 years)
referred for staging (n=20) or restaging (n=25), a reliable reference
standard was available. The reference standard was established by
clinical follow-up including additional imaging in all patients and
additional biopsy in 26 patients.
The histological tumor type was follicular lymphoma in 47%
(n=21) of patients, nodal and extranodal marginal zone lymphoma
in 26% (n=12), small lymphocytic lymphoma in 9% (n=4), mantle
cell lymphoma in 9% (n=4) as well as lymphoplasmocytic
lymphoma (n=1), cutaneous T-cell lymphoma (n=2), and T-cell/
NK lymphoproliferative disorder (n=1) in altogether 9% (see
Table 1).
Image Acquisition
PET/CT was performed using the Reveal RT scanner (Siemens
Medical Systems). This system combines a dual-slice-detector CT
scanner (Somatom Emotion) with an ECAT ACCEL PET scanner.
The characteristics of the device have been described in detail
previously [20].
While resting on a reclining chair, the patients received a
7.77 MBq (0.21 mCi) per kg bodyweight of
18F-FDG intravenously
(up to a maximum of 740 MBq [20 mCi]) and were asked to drink
900 mL of barium sulfate. The imaging sequence began 45 min
after tracer injection. All patients were positioned on the imaging
table with their arms up. After determining the imaging field (base
of skull to mid thighs) with an initial scout scan, CT acquisition
with intravenous contrast material was performed using the
following parameters: 130 kVp, 120 mAs, 1-s tube rotation, 4-
mm slice collimation, and bed speed of 8 mm/s (i.e., pitch of 2).
The CT scan was followed by the PET emission scan, using a
weight-based protocol as recently described [20, 21]. Scanning
encompassed six to eight bed positions (depending on patient
height) from the mid-thigh to the base of the skull. PET images
were acquired in 3D mode. Patients were instructed to breathe
shallowly during the PET and CT portions of the study to minimize
misregistration between PET and CT images [22].
Image Reconstruction
CT images were reconstructed using conventional filtered back-
projection, at 3.4-mm axial intervals to match the slice separation of
the PET data. PET images were reconstructed by using iterative
algorithms (ordered-subsets expectation maximization, two itera-
tions and eight subsets) to a final image resolution of 8.8 mm at full
width at half maximum. Attenuation was corrected by mapping the
CT Hounsfield units to the linear attenuation coefficients as
previously described [23].
Image Analysis
PET, CT, and PET/CT acquired in this retrospectively enrolled
population were interpreted prospectively as follows: CT and PET
images were interpreted independently by one radiologist and one
nuclear medicine specialist, respectively, who were blinded to any
additional clinical and other imaging findings. PET/CT studies
were read in consensus.
A lesion was classified as positive on PET if there was focally
increased FDG uptake above background that was not explained by
physiological activity. A lesion on CT was classified by lymph node
size criteria (diameter 910 mm) or extra-nodal structural anatomical
abnormality.
Unlike aggressive disease, indolent lymphomas do not exhibit
uniformly increased FDG uptake [12–15]. Therefore, our image
interpretation criteria were biased toward CT as follows: on PET/
CT, a lymph node was classified as abnormal if there was increased
FDG uptake and/or abnormal size regardless of FDG uptake. Extra-
nodal lesions were interpreted as abnormal if they exhibited focally
increased FDG uptake and/or pathological anatomical features on
CT (regardless of the FDG uptake).
Staging and Analysis of Nodal Regions
Based on the lymph node regions originally defined by Kaplan and
Rosenberg[24], we analyzed 13 lymph node regions per patients.
Therefore, a total of 585 lymph node regions were analyzed. The
patient stage was determined based on the Ann Arbor classification
[25] from the number of positive nodal and extra-nodal regions by
PET, CT, and PET/CT.
Table 1. Patient characteristics
Number of patients 45
Gender
Female 19
Male 26
Age (years)
Mean 56
Range 21–78
Histology
Follicular 21 (47%)
Marginal Zone (including MALT) 12 (26%)
Small lymphocytic lymphoma 4 (9%)
Mantle cell lymphoma 4 (9%)
Others (lymphoplasmocytic, cutaneous T-cell, T-cell/ NK) 4 (9%)
Scan Indication
Initial staging 20
Restaging 25
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For the calculation of SUV, circular regions of interest (15-mm
diameter) were placed on consecutive axial images of lesions
visually identified to have abnormally increased FDG uptake. In the
absence of visual FDG uptake, the biopsy site was used for the
determination of SUV. The SUV was calculated as:
SUV ¼
decay   correctedactivity kBq ðÞ =tissuevolume ml ðÞ
injected   FDGactivity kBq ðÞ =bodyweight g ðÞ
To minimize partial volume effects and assure reproducibility of
measurements, the maximum SUV (SUVmax) was used.
Immunohistochemical Staining with Ki-67
Ki-67 staining results from biopsies obtained for diagnostic
purposes were available in 29 patients who had not undergone
treatment between the biopsy and the PET/CT. Biopsies were
performed within 4.38±4.79 weeks (0–16.43) of the PET/CT. The
Ki-67 labeling index reflects cell proliferative activity and is
defined as the percentage of nuclei stained per total number of
nuclei in the sample. The immunohistochemistry and determination
of the Ki-67 labeling index were performed according to standard
protocol and routine at our institution [26, 27].
Proliferative activity by Ki-67 staining was then correlated with
the SUVmax of the biopsied site.
SUVmax and Histology
SUVmax was also correlated with histology to determine whether
the type of indolent lymphoma determines FDG uptake.
Standard of Reference
All patients had lymph node biopsy for histological diagnosis of
disease. For ethical reasons, systematic biopsy of all sites for staging
wasnotperformed.Clinicalevaluationandfollow-upfor71±32weeks
(range,16to131weeks)forallpatients,biopsy(n=26), and additional
imaging consisting of CT, MRI or PET/CT (n=35) performed 4.55±
4.25 weeks after the initial scan (range, 0 to 17 weeks) served as the
referencestandard.Concordantpositivefindingsofclinicalevaluation,
CT, PET, and PET/CT were regarded as true sites of disease.
Concordant negative findings of clinical evaluation, CT, PET, and
PET/CT were regarded as true absence of diseases. In cases of
discordance between PET, CT, and PET/CT, response to treatment
and follow-up data were used to assess the overall accuracy of the
patient’s disease status. Lesions were considered true positive if
abnormalities either persisted on a follow-up PET or CT scan with no
interval treatment or resolved on a follow-up scan in patients that had
received interval treatment. Conversely, lesions that resolved on
follow-up scanning without interval treatment were considered false
positive.
Statistics
Using the standard of reference, sensitivity, specificity, and
accuracy were calculated [28]. In addition, comparison between
groups was performed using the unpaired t test and McNemar test.
Correlations were sought using the Pearson correlation. A pG0.05
was considered significant.
Results
Thirty-three of 45 patients had evidence of active disease
with a total of 117 of 585 nodal regions involved according
to the reference standard. In addition, a total of 36 extranodal
lesions were identified by the reference standard.
Staging Performance
Compared to the reference standard, the correct stage was
determined by PET in 62% of patients (n=28), by CT in
58% (n=26), and by PET/CT in 76% (n=34). PET
incorrectly assigned a higher stage in 7% of patients (n=3),
CT in 7% (n=3), and PET/CT in 9% (n=4). PET incorrectly
assigned a lower stage in 31% (n=14),CTin36%(n=16),and
PET/CT in 16% (n=7). There was no significant difference
between the number of patients correctly staged by PET and
PET/CT (p=0.24), and PET/CT only demonstrated a trend
toward better performance than CT (p=0.079).
In detail, PET/CT correctly resulted in a higher stage than
CT in 18% (n=8) of the patients and in a higher stage than
PET in 20% (n=9) of patients. PET/CT correctly down-
staged 4% (n=2) of patients compared to PET. Due to the
selected image interpretation criteria, down-staging of CT by
PET/CT was not possible.
Positive Nodal and Extra-nodal Regions
From a total of 585 nodal regions, PET/CT correctly
diagnosed 92 nodal regions as positive for lymphomatous
involvement and 458 as disease free vs 68 and 449 for PET
and 64 and 459 for CT, respectively. The number of false-
positive and false-negative nodal regions were eight and 27
for PET/CT, 18 and 50 for PET, and eight and 54 for CT,
respectively. The respective sensitivities, specificities, and
accuracies were 99%, 100%, and 99.8% for PET/CT, 68%,
97.5%, and 92.2% for PET, and 70%, 100%, and 94.7% for
CT. PET/CT performed significantly better than PET (pG
0.001 for sensitivity, specificity, and accuracy) and CT (pG
0.001 for sensitivity and accuracy). Differences between
PET and CT were not significant for sensitivity, significant
for specificity (pG0.001), and tended to be significant for
accuracy (p=0.089; see Table 2).
PET/CT was also significantly better in detecting
extra-nodal lesions than CT (pG0.016) and PET (p=
0.06). Of the 36 extranodal lesions by gold standard
(tissues /organs involved were the parotid gland, lung,
stomach, liver, adrenal gland, kidney, spleen, skin,
conjunctiva, meninges, the bone marrow, as well as
muscle and soft tissue), PET/CT detected 25 extra-nodal
lesions, CT 16, and PET nine (see Figs. 1 and 2). Of
eight bone marrow sites, three were identified by PET,
four by PET/CT, and none by CT alone. Of eight sites
of lung involvement, PET only noted three, whereas CT
and PET/CT correctly diagnosed all eight. From nine
sites of soft tissue involvement, PET noted one, CT four,
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PET correctly noted two, CT four, and PET/CT five.
The above includes six patients with extranodal marginal
zone lymphoma. One of these six patients did not have
active disease. Of the five remaining patients, organ
involvement included the meninges, the parotid gland,
conjunctiva, lung, liver, stomach, spleen, kidney, and the
skin.
SUVmax vs Proliferative Activity and Histology
SUVmax ranged from 0.4 to 15.4 (mean±SD, 3.7±4.1) in
follicular and from 0.8 to 9.8 (2.2±2.1) in non-follicular
indolent lymphomas. The highest SUVmax as well as the
lowest SUVmax occurred in follicular grade-1 lymphomas.
There was also a wide range of Ki-67 staining with the
lowest proliferative activity observed in MALT lymphoma
and the highest in mantle cell lymphoma. The correlation of
SUVmax and Ki-67 index was not statistically significant.
No significant difference was found between the SUVmax
of the various types of indolent lymphoma.
Discussion
For the group of patients studied, PET/CT was able to add
clinically important information not available from CT or
PET alone. On a regional-based analysis of patients with
indolent lymphoma, PET/CT performed significantly better
than PET and CT in correctly classifying lymph node groups
as positive or negative for lymphomatous involvement. PET/
CT was also able to detect more extra-nodal sites of disease
than either CT or PET. There was no significant difference
between the number of patients correctly staged by PET and
PET/CT, and PET/CT only demonstrated a trend toward
better performance than CT (p=0.079).
Few papers have looked at the value of FDG-PET over
conventional imaging specifically for the staging of indolent
lymphoma. Jerusalem et al. [13] reported that, in 42 patients
with indolent lymphoma, PET was able to identify more
lymph node areas infiltrated by indolent lymphoma com-
pared to conventional staging procedures. Contrary to the
findings of Jerusalem et al., we found no significant
difference between the sensitivity of PET or CT for the
detection of nodal groups with disease. However, PET/CT
was significantly better in detecting nodal disease than
either modality. Similarly, PET/CT detected more extra-
nodal disease sites than PET or CT. For the overall staging
of disease, Jerusalem et al. reported that PET plus a bone
marrow biopsy compared to conventional staging procedures
(also including a bone marrow biopsy) observed the same
stage in 37 patients, a higher stage by PET in two patients,
Table 2. Performance for detection of nodal disease
Sensitivity Specificity Accuracy
PET 68 97.5 92.2
CT 70 100 94.7
PET/CT 99 100 99.8
pG0.001 vs PET, CT pG0.001 vs PET pG0.001 vs PET, CT
Fig. 1. A 59-year-old woman with a history of cutaneous T-
cell lymphoma. Fused coronal (a) and axial PET/CT (b) slices
demonstrate left flank skin involvement (arrow) missed on CT
(c) and PET (d) interpretation.
Fig. 2. A 62-year-old man with history of mantle cell lympho-
ma. Fused coronal (a)a n da x i a lP E T / C T( b) slices demonstrate
disease related FDG uptake in left obturator adenopathy (arrow)
missed on CT (c)a n dP E T( d) interpretation.
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patients. In our study, PET/CT staged more patients
correctly than either PET or CT, although the differences
for overall staging only demonstrated a statistical trend to
significance. Najjar et al. [29] reported a similar observation
finding the combined information of separately acquired CT
and PET more sensitive for staging indolent lymphoma than
either modality alone. Disease occurring in normal appearing
lymph nodes or extra-nodal sites can be picked up by PET.
Conversely, CT can detect disease missed by PET either
because of size or because of the absence of FDG uptake
frequently encountered in the setting of indolent lymphoma.
The additional value of fused imaging with PET/CT over
side by side reading of CT and PET has been reported for
multiple malignancies in general [30] as well as specifically
for lymphoma [6, 7].
Data on the correlation between proliferative activity
determined by Ki-67 staining and glucose metabolism in
lymphomas, as measured by FDG uptake, are controversial.
Okada et al. [18] report a positive correlation between
proliferation and FDG uptake in a small series of patients
with malignant lymphomas. We observed no statistically
significant correlation between SUVmax and percentage of
cells that stained positive with Ki-67. We therefore feel that,
in indolent lymphoma, SUVmax cannot substitute for the
prognostic value provided by Ki-67 reported in indolent
lymphoma [31].
Comparing the SUVmax of the different subgroups of
indolent lymphoma in our study, we found no significant
differences in SUVmax. Although Karam et al. [12] did note
a significantly higher SUV in follicular lymphoma than
other indolent lymphoma, our findings are more in line with
Schoeder et al. [17], noting no significant difference in FDG
uptake within the histological subtypes of indolent lympho-
ma. Thus, it is likely that histological classification based on
SUV measurements cannot be a substitute for the histolog-
ical diagnosis based on actual tissue. However, as Bodet-
Milin et al. reported [32], PET/CT might be of value in the
assessment of patients with indolent lymphoma suspected to
have undergone histological transformation of their indolent
lymphomas, since this usually results in a significant
increase of FDG uptake at the sites of transformation.
Limitations
Since biopsy of every suspicious lesion would not be ethical, a
surrogate gold standard had to be found. Concordant positive
findings of clinical evaluation, CT, PET, and PET/CT were
regarded as true sites of disease. Concordant negative findings
of clinical evaluation, CT, PET, and PET/CT were regarded as
true absence of disease. In cases of discordance between PET,
CT, and PET/CT, response to treatment and follow-up data
wereusedtoassessthe overall accuracyofthe patient’sd i s e a s e
status. Lesions were considered true positive if abnormalities
eitherpersistedona follow-upPETorCTscanwithnointerval
treatment or resolved on a follow-up scan in patients that had
received interval treatment. Conversely, lesions that resolved
on follow-up scanning without interval treatment were consi-
dered false positive.Sinceinitialtreatment responsetoindolent
lymphoma is excellent [33–35], lesions that would have
persisted despite interval treatment would also have been
considered false positive. However, we did not encounter any
patient in which this would have been the case.
The patient population studied was heterogeneous, and
larger studies evaluating the individual subtypes of indolent
lymphomas might be warranted to confirm our results.
The relatively low number of patients with a reliable
reference standard (45 out of 301) likely results from the
clinical course low grade lymphomas frequently take, i.e.,
long periods of clinically inactive disease only leading to a
clinical evaluation by the treating physician if symptoms
occur.
Conclusion
PET/CT provides important additional information over PET
and CT for the staging and re-staging of patients with
indolent lymphoma. Thus, the application of PET/CT rather
than CT or PET is likely to be of benefit in the management
of patients with indolent lymphoma. Given the frequent
absence of significant FDG uptake in indolent lymphomas,
in the untreated patient, enlarged nodes detected on CT
should be regarded as pathological even in the absence of
FDG uptake. On subsequent post-treatment scans, node size
should be used to evaluate for treatment response rather than
FDG uptake.
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